Her2-positive Lung Cancer Treated With Dedicated Drug

Clinical trial NCT03845270 · COMPLETED

Trial details

NCT number: NCT03845270
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage III HER2 Gene Mutation

Start date: 2019-05-17
Primary completion: 2021-02-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.